Tag Archive for: Q3 report

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

· Closing of the €115 million licensing transaction with SERB · Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026 · The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase) Lund, Sweden, November 11, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced […]

AC Immune Third Quarter 2026 Financial and Corporate Update

Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead […]

4SC publishes Q3 2024 report

Planegg-Martinsried, Germany, 17 October 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, today published its Q3 2024 report, presenting all material developments up to 30 September 2024, as well as the Company’s current outlook. The full report is available for […]

© Optimum Strategic Communications.